Aspen Neuroscience Completes Cohort 4 in ASPIRO Parkinson’s Trial
SAN DIEGO, June 30, 2026 Aspen Neuroscience, Inc. has announced the successful completion of Cohort 3 and Cohort 4...
Parkinson’s Disease
Advertisement
iQure Pharma Wins MJFF Grant for Parkinson’s Research
PRINCETON, N.J. | June 18, 2026 iQure Pharma has been awarded a research grant from The Michael J. Fox...
Insilico Medicine Reports First Human Dosing of ISM8969
HONG KONG, June 18, 2026 Insilico Medicine, a clinical-stage biotechnology company powered by generative artificial intelligence (AI), has announced...
Bial Discontinues Pariceract After Phase 2b ACTIVATE Trial Miss
PORTO, Portugal, June 9, 2026 Bial announced topline results from its Phase 2b ACTIVATE study evaluating BIA 28-6156 (pariceract)...
Amneal Reports Positive Phase 4 ELEVATE-PD Results for CREXONT
BRIDGEWATER, N.J., June 5, 2026 Amneal Pharmaceuticals announced positive interim results from the ongoing Phase 4 ELEVATE-PD study, demonstrating...
Advertisements
Merz Therapeutics Unveils New Insights Into Parkinson’s OFF Episodes at WPC 2026
FRANKFURT, Germany & RALEIGH, N.C. — May 28, 2026 Merz Therapeutics presented new research at the World Parkinson Congress...
TreeFrog’s TFG-001 Shows Strong Parkinson’s Recovery Data
BORDEAUX, France, May 25, 2026 TreeFrog Therapeutics announced new preclinical data showing that its investigational 3D neural microtissue cell...
Biogen, Denali End BIIB122 Parkinson’s Program
CAMBRIDGE, Massachusetts and SOUTH SAN FRANCISCO, California, May 21, 2026 Biogen Inc. and Denali Therapeutics Inc. announced that the...
AndzonBio2 and Cambridge Partner on Neuroinflammation Therapies
PARIS and CAMBRIDGE, UK, May 13, 2026 AndzonBio2 announced a strategic collaboration with the ALBORADA Drug Discovery Institute (ADDI)...
XellSmart Advances Phase 2 Parkinson’s Cell Therapy Trial
Suzhou, China | April 14, 2026 XellSmart has announced the initiation of a multicenter Phase II clinical trial evaluating...
Advertisement
